Evidence map›Paper›PMID 34423922›Full record

ArticleACR open rheumatology2021

Poor Prognosis of COVID-19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross-Sectional Population Study Of 252 119 Patients.

Isabela Maria Bertoglio, Juliana Miranda de Lucena Valim, Danielle Daffre, Nádia Emi Aikawa, Clovis Artur Silva, Eloisa Bonfá, Michelle Remião Ugolini-Lopes

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACR open rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Review
  9. Mechanical ventilation associated pneumonia during ECMO therapy. A challenge for the Intensive Care physician.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Isabela Maria BertoglioHospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Juliana Miranda de Lucena ValimHospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Danielle DaffreHospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Nádia Emi AikawaHospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-7585-4348
Clovis Artur SilvaHospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Eloisa BonfáHospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-0520-4681
Michelle Remião Ugolini-LopesHospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-3729-129X
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 05242/2019-9Conselho Nacional de Desenvolvimento Científico e Tecnológico 304984/2020-5Fundação de Amparo à Pesquisa do Estado de São Paulo 2015/03756-4
6 · The paper itself

Abstract

objectiveCoronavirus disease 2019 (COVID-19) has progressed rapidly around the world, reaching a lethality of up to 20% due to acute respiratory distress syndrome (ARDS). This latter condition is a relevant concern for systemic lupus erythematosus (SLE); however, data on this topic are limited to few case series. Our objective was to evaluate in hospitalized patients with SLE and with COVID-19-associated ARDS (confirmed by reverse transcription-polymerase chain reaction) the risk of mortality and combined poor outcomes (death, intensive care unit [ICU] admission, and/or mechanical ventilation [MV] use) and to compare with that of patients without SLE.

methodsThis is a nationwide cross-sectional study of patients with severe acute respiratory syndrome coronavirus 2 nested in the national Influenza Epidemiological Surveillance Information System (Sistema de Informação de Vigilância Epidemiológica da Gripe [SIVEP-gripe]). Mortality rates, frequencies of ICU admissions, and MV use for 319 patients with SLE and 251 800 patients without SLE were calculated as well as relative risks (RRs). A fully adjusted multiple logistic regression was performed to adjust factors, such as age and well-known comorbidities, that might impact worse outcomes.

resultsPatients with SLE had an increased risk of death and combined poor outcome compared with patients without SLE (RR = 1.738, 95% confidence interval [CI]: 1.557-1.914, and RR = 1.391, 95% CI: 1.282-1.492, respectively). Among all investigated comorbidities, SLE yielded the higher risk of death and combined poor outcomes (RR = 2.205, 95% CI: 1.780-2.633, and RR = 1.654, 95% CI: 1.410-1.88, respectively).

conclusionsThis study provides novel evidence that patients with SLE hospitalized because of COVID-19 have significantly higher risks of death and poor outcomes compared with patients without comorbidities and patients with other comorbidities.

Identifiers

PMID34423922
PMCPMC8593786
OpenAlexW3193640668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.